Technology
Health
Biotechnology

Eiger BioPharmaceuticals

$13.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.19 (1.41%) Today
+$0.19 (1.41%) Today

Why Robinhood?

You can buy or sell EIGR and other stocks, options, ETFs, and crypto commission-free!

About

Eiger BioPharmaceuticals, Inc. Common Stock, also called Eiger BioPharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.

Employees
18
Headquarters
Palo Alto, California
Founded
2008
Market Cap
259.36M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
130.38K
High Today
$13.75
Low Today
$13.55
Open Price
$13.55
Volume
9.84K
52 Week High
$18.00
52 Week Low
$8.20

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2016 IPO
US

News

PR NewswireMar 13

Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019

PALO ALTO, Calif., March 13, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced a late-breaker oral presentation of Phase 2 LIMT HDV ( L ambda I nterferon M ono T herapy in H epatitis D elta V irus) end of study 24 week post-treatment results will be presented at The International Liver Congress™ 2019 in Vienna, Austria, April 10 to 13. Peginterferon Lambda is a f...

134
Guru FocusMar 11

Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit

PALO ALTO, Calif., March 11, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the Jefferies HBV Investor Summit in New York City. The HDV Investor Summit will be held on March 18th at the Jefferies Conference Center and will include company presentations, an expert panel, and one-on-one meetin...

46
Simply Wall StMar 8

The Eiger BioPharmaceuticals (NASDAQ:EIGR) Share Price Is Up 38% And Shareholders Are Holding On

The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you could make more than that. For example, the Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) share price is up 38% in the last year, clearly besting than the market return of around -1.0% (not including dividends). If it can keep that out-performance up over the long term, investors will do very well! We’ll need to follow Eiger BioPharmaceuticals for a while to get a better sense of its share p...

111

Earnings

-$1.37
-$1.16
-$0.95
-$0.74
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.82 per share
Actual
-$0.92 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.